Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer

Trial Profile

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 13 Dec 2018 Planned primary completion date changed from 13 May 2021 to 22 Jun 2021.
    • 13 Dec 2018 Planned initiation date changed from 24 May 2019 to 21 Jun 2019.
    • 06 Dec 2018 Planned End Date changed from 14 Apr 2022 to 1 May 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top